-
1
-
-
0029835349
-
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
-
Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Kato T, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557
-
(1996)
Anticancer Drugs
, vol.7
, pp. 548-557
-
-
Shirasaka, T.1
Shimamato, Y.2
Ohshimo, H.3
Yamaguchi, M.4
Kato, T.5
Kato, T.6
Fukushima, M.7
-
2
-
-
0034029776
-
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. for the S-1 Cooperative Gastric Cancer Study Group
-
Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58:191-197
-
(2000)
Oncology
, vol.58
, pp. 191-197
-
-
Koizumi, W.1
Kurihara, M.2
Nakano, S.3
Hasegawa, K.4
-
3
-
-
0032189218
-
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients
-
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
-
(1998)
Eur J Cancer
, vol.34
, pp. 1715-1720
-
-
Sakata, Y.1
Ohtsu, A.2
Horikoshi, N.3
Sugimachi, K.4
Mitachi, Y.5
Taguchi, T.6
-
4
-
-
0028276113
-
Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group
-
Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N (1994) Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Jpn J Cancer Chemother 2:1033-1038
-
(1994)
Jpn J Cancer Chemother
, vol.2
, pp. 1033-1038
-
-
Futatsuki, K.1
Wakui, A.2
Nakao, I.3
Sakata, Y.4
Kambe, M.5
Shimada, Y.6
Yoshino, M.7
Taguchi, T.8
Ogawa, N.9
-
5
-
-
0036654749
-
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: A phase II trial
-
Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, Daglish B, Boudraa Y, Kim WS, Heo DS, Kim NK (2002) Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32:248-254
-
(2002)
Jpn J Clin Oncol
, vol.32
, pp. 248-254
-
-
Bang, Y.J.1
Kang, W.K.2
Kang, Y.K.3
Kim, H.C.4
Jacques, C.5
Zuber, E.6
Daglish, B.7
Boudraa, Y.8
Kim, W.S.9
Heo, D.S.10
Kim, N.K.11
-
6
-
-
0034830598
-
Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions
-
Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T (2001) Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12:1133-1137
-
(2001)
Ann Oncol
, vol.12
, pp. 1133-1137
-
-
Yamada, Y.1
Shirao, K.2
Ohtsu, A.3
Boku, N.4
Hyodo, I.5
Saitoh, H.6
Miyata, Y.7
Taguchi, T.8
-
7
-
-
4644271767
-
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer
-
Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY (2004) A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15:1344-1347
-
(2004)
Ann Oncol
, vol.15
, pp. 1344-1347
-
-
Hong, Y.S.1
Song, S.Y.2
Lee, S.I.3
Chung, H.C.4
Choi, S.H.5
Noh, S.H.6
Park, J.N.7
Han, J.Y.8
Kang, J.H.9
Lee, K.S.10
Cho, J.Y.11
-
8
-
-
18544367472
-
Current status and future prospects of chemotherapy for metastatic gastric cancer: A review
-
Ohtsu A (2005) Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 8:95-102
-
(2005)
Gastric Cancer
, vol.8
, pp. 95-102
-
-
Ohtsu, A.1
-
9
-
-
0842330394
-
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer
-
Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M (2003) Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 8:2207-2212
-
(2003)
Br J Cancer
, vol.8
, pp. 2207-2212
-
-
Koizumi, W.1
Tanabe, S.2
Saigenji, K.3
Ohtsu, A.4
Boku, N.5
Nagashima, F.6
Shirao, K.7
Matsumura, Y.8
Gotoh, M.9
-
10
-
-
33644833992
-
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
-
Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB, Yanagihara R, Phan AT, Yao JC, Strumberg D (2006) Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:663-667
-
(2006)
J Clin Oncol
, vol.24
, pp. 663-667
-
-
Ajani, J.A.1
Lee, F.C.2
Singh, D.A.3
Haller, D.G.4
Lenz, H.J.5
Benson, A.B.6
Yanagihara, R.7
Phan, A.T.8
Yao, J.C.9
Strumberg, D.10
-
11
-
-
33646153542
-
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
-
Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, Kawano T, Sugihara K (2006) Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 94:1130-1135
-
(2006)
Br J Cancer
, vol.94
, pp. 1130-1135
-
-
Inokuchi, M.1
Yamashita, T.2
Yamada, H.3
Kojima, K.4
Ichikawa, W.5
Nihei, Z.6
Kawano, T.7
Sugihara, K.8
-
12
-
-
33745091156
-
Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
-
Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjo F, Sakata Y (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94:1803-1808
-
(2006)
Br J Cancer
, vol.94
, pp. 1803-1808
-
-
Yamaguchi, K.1
Shimamura, T.2
Hyodo, I.3
Koizumi, W.4
Doi, T.5
Narahara, H.6
Komatsu, Y.7
Kato, T.8
Saitoh, S.9
Akiya, T.10
Munakata, M.11
Miyata, Y.12
Maeda, Y.13
Takiuchi, H.14
Nakano, S.15
Esaki, T.16
Kinjo, F.17
Sakata, Y.18
-
13
-
-
33845615923
-
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer
-
Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, Nakamura J, Ohsawa H, Nakabayashi T, Takeuchi K, Asao T, Kuwano H (2006) Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 95:1642-1647
-
(2006)
Br J Cancer
, vol.95
, pp. 1642-1647
-
-
Mochiki, E.1
Ohno, T.2
Kamiyama, Y.3
Aihara, R.4
Haga, N.5
Ojima, H.6
Nakamura, J.7
Ohsawa, H.8
Nakabayashi, T.9
Takeuchi, K.10
Asao, T.11
Kuwano, H.12
-
14
-
-
33846271497
-
Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study
-
Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA (2007) Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 109:33-40
-
(2007)
Cancer
, vol.109
, pp. 33-40
-
-
Lenz, H.J.1
Lee, F.C.2
Haller, D.G.3
Singh, D.4
Benson III, A.B.5
Strumberg, D.6
Yanagihara, R.7
Yao, J.C.8
Phan, A.T.9
Ajani, J.A.10
-
15
-
-
15444363796
-
Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer
-
Nagashima F, Ohtsu A, Yoshida S, Ito K (2005) Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 8:6-11
-
(2005)
Gastric Cancer
, vol.8
, pp. 6-11
-
-
Nagashima, F.1
Ohtsu, A.2
Yoshida, S.3
Ito, K.4
-
16
-
-
0007605328
-
Adverse drug reaction criteria of the Japan Society of Clinical Oncology
-
Japan Society of Clinical Oncology
-
Japan Society of Clinical Oncology (1997) Adverse drug reaction criteria of the Japan Society of Clinical Oncology. Int J Clin Oncol 2:177-179
-
(1997)
Int J Clin Oncol
, vol.2
, pp. 177-179
-
-
-
17
-
-
0016916438
-
Prediction of creatinine clearance from serum creatinine
-
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
-
(1976)
Nephron
, vol.16
, pp. 31-41
-
-
Cockcroft, D.W.1
Gault, M.H.2
-
18
-
-
0035871538
-
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
-
Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292
-
(2001)
J Clin Oncol
, vol.19
, pp. 2282-2292
-
-
Hoff, P.M.1
Ansari, R.2
Batist, G.3
Cox, J.4
Kocha, W.5
Kuperminc, M.6
Maroun, J.7
Walde, D.8
Weaver, C.9
Harrison, E.10
Burger, H.U.11
Osterwalder, B.12
Wong, A.O.13
Wong, R.14
-
19
-
-
0035503151
-
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
-
Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106
-
(2001)
J Clin Oncol
, vol.19
, pp. 4097-4106
-
-
Van Cutsem, E.1
Twelves, C.2
Cassidy, J.3
Allman, D.4
Bajetta, E.5
Boyer, M.6
Bugat, R.7
Findlay, M.8
Frings, S.9
Jahn, M.10
McKendrick, J.11
Osterwalder, B.12
Perez-Manga, G.13
Rosso, R.14
Rougier, P.15
Schmiegel, W.H.16
Seitz, J.F.17
Thompson, P.18
Vieitez, J.M.19
Weitzel, C.20
Harper, P.21
more..
-
20
-
-
21244497388
-
Capecitabine as adjuvant treatment for stage III colon cancer
-
Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704
-
(2005)
N Engl J Med
, vol.352
, pp. 2696-2704
-
-
Twelves, C.1
Wong, A.2
Nowacki, M.P.3
Abt, M.4
Burris, H.5
Carrato, A.6
Cassidy, J.7
Cervantes, A.8
Fagerberg, J.9
Georgoulias, V.10
Husseini, F.11
Jodrell, D.12
Koralewski, P.13
Kroning, H.14
Maroun, J.15
Marschner, N.16
McKendrick, J.17
Pawlicki, M.18
Rosso, R.19
Schuller, J.20
Seitz, J.F.21
Stabuc, B.22
Tujakowski, J.23
Van Hazel, G.24
Zaluski, J.25
Scheithauer, W.26
more..
-
21
-
-
0036305932
-
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function
-
Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T (2002) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol 50:25-32
-
(2002)
Cancer Chemother Pharmacol
, vol.50
, pp. 25-32
-
-
Ikeda, M.1
Furukawa, H.2
Imamura, H.3
Shimizu, J.4
Ishida, H.5
Masutani, S.6
Tatsuta, M.7
Kawasaki, T.8
Satomi, T.9
-
23
-
-
10744224587
-
Phase I study of S-1. S-1 Study Group
-
Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagoshi S, Nakao I (1997) Phase I study of S-1. S-1 Study Group. Jpn J Cancer Chemother 24:2253-2264
-
(1997)
Jpn J Cancer Chemother
, vol.24
, pp. 2253-2264
-
-
Taguchi, T.1
Inuyama, Y.2
Kanamaru, R.3
Hasegawa, K.4
Akazawa, S.5
Niitani, H.6
Furue, H.7
Kurihara, M.8
Ota, K.9
Suga, S.10
Ariyoshi, Y.11
Takai, S.12
Shimoyama, T.13
Toge, T.14
Takashima, S.15
Sugimachi, K.16
Hara, Y.17
Fujita, H.18
Kimura, K.19
Saito, T.20
Tsukagoshi, S.21
Nakao, I.22
more..
-
24
-
-
0031060433
-
Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats
-
Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39:205-211
-
(1997)
Cancer Chemother Pharmacol
, vol.39
, pp. 205-211
-
-
Takechi, T.1
Nakano, K.2
Uchida, J.3
Mita, A.4
Toko, K.5
Takeda, S.6
Unemi, N.7
Shirasaka, T.8
-
25
-
-
0141841803
-
Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
-
Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S (2003) Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 89:816-820
-
(2003)
Br J Cancer
, vol.89
, pp. 816-820
-
-
Yamada, Y.1
Hamaguchi, T.2
Goto, M.3
Muro, K.4
Matsumura, Y.5
Shimada, Y.6
Shirao, K.7
Nagayama, S.8
-
26
-
-
0037570623
-
S-1 in gastric cancer: A comprehensive review
-
Suppl 1
-
Maehara Y (2003) S-1 in gastric cancer: a comprehensive review. Gastric Cancer 6(Suppl 1):2-8
-
(2003)
Gastric Cancer
, vol.6
, pp. 2-8
-
-
Maehara, Y.1
-
27
-
-
33745929348
-
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers
-
Ajani J (2006) Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107:221-231
-
(2006)
Cancer
, vol.107
, pp. 221-231
-
-
Ajani, J.1
-
28
-
-
9144238357
-
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial
-
Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14:1735-1743
-
(2003)
Ann Oncol
, vol.14
, pp. 1735-1743
-
-
Scheithauer, W.1
McKendrick, J.2
Begbie, S.3
Borner, M.4
Burns, W.I.5
Burris, H.A.6
Cassidy, J.7
Jodrell, D.8
Koralewski, P.9
Levine, E.L.10
Marschner, N.11
Maroun, J.12
Garcia-Alfonso, P.13
Tujakowski, J.14
Van Hazel, G.15
Wong, A.16
Zaluski, J.17
Twelves, C.18
-
29
-
-
0036235128
-
First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
-
Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566-575
-
(2002)
Ann Oncol
, vol.13
, pp. 566-575
-
-
Cassidy, J.1
Twelves, C.2
Van Cutsem, E.3
Hoff, P.4
Bajetta, E.5
Boyer, M.6
Bugat, R.7
Burger, U.8
Garin, A.9
Graeven, U.10
McKendric, J.11
Maroun, J.12
Marshall, J.13
Osterwalder, B.14
Perez-Manga, G.15
Rosso, R.16
Rougier, P.17
Schilsky, R.L.18
-
30
-
-
0023187085
-
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
-
Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206
-
(1987)
Cancer Res
, vol.47
, pp. 2203-2206
-
-
Heggie, G.D.1
Sommadossi, J.P.2
Cross, D.S.3
Huster, W.J.4
Diasio, R.B.5
-
31
-
-
0014834207
-
Biochemical basis for fluorouracil neurotoxicity. the role of Krebs cycle inhibition by fluoroacetate
-
Koenig H, Patel A (1970) Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 23:155-160
-
(1970)
Arch Neurol
, vol.23
, pp. 155-160
-
-
Koenig, H.1
Patel, A.2
-
32
-
-
0027472160
-
The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy
-
Robben NC, Pippas AW, Moore JO (1993) The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 71:493-509
-
(1993)
Cancer
, vol.71
, pp. 493-509
-
-
Robben, N.C.1
Pippas, A.W.2
Moore, J.O.3
-
33
-
-
0035985332
-
Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil
-
Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M (2002) Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 13:797-801
-
(2002)
Ann Oncol
, vol.13
, pp. 797-801
-
-
Frickhofen, N.1
Beck, F.J.2
Jung, B.3
Fuhr, H.G.4
Andrasch, H.5
Sigmund, M.6
-
34
-
-
0038579652
-
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. a trial performed by the EORTC Early Clinical Studies Group (ECSG)
-
EORTC Early Clinical Studies Group
-
Chollet P, Schöffski P, Weigang-Köhler K, Schellens JH, Cure H, Pavlidis N, Grünwald V, De Boer R, Wanders J, Fumoleau P; EORTC Early Clinical Studies Group (2003) Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39:1264-1270
-
(2003)
Eur J Cancer
, vol.39
, pp. 1264-1270
-
-
Chollet, P.1
Schöffski, P.2
Weigang-Köhler, K.3
Schellens, J.H.4
Cure, H.5
Pavlidis, N.6
Grünwald, V.7
De Boer, R.8
Wanders, J.9
Fumoleau, P.10
-
35
-
-
18244414936
-
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
-
van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G (2000) Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 18:2772-2779
-
(2000)
J Clin Oncol
, vol.18
, pp. 2772-2779
-
-
Van Groeningen, C.J.1
Peters, G.J.2
Schornagel, J.H.3
Gall, H.4
Noordhuis, P.5
De Vries, M.J.6
Turner, S.L.7
Swart, M.S.8
Pinedo, H.M.9
Hanauske, A.R.10
Giaccone, G.11
-
36
-
-
33646591539
-
Disparities in gastric cancer chemotherapy between the East and West
-
Ohtsu A, Yoshida S, Saijo N (2006) Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 24:2188-2196
-
(2006)
J Clin Oncol
, vol.24
, pp. 2188-2196
-
-
Ohtsu, A.1
Yoshida, S.2
Saijo, N.3
-
37
-
-
1542269125
-
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors
-
Schöffski P (2004) The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15:85-106
-
(2004)
Anticancer Drugs
, vol.15
, pp. 85-106
-
-
Schöffski, P.1
|